- Conditions
- Metabolic Disturbance
- Interventions
- nicotinamide riboside
- Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 124
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin QD (once daily) for 7 days
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 6
- States / cities
- Cypress, California • DeLand, Florida • Miami, Florida + 3 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Nicotinamide Riboside (NR), Placebo
- Dietary Supplement · Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Aging
- Interventions
- Nicotinamide riboside, Placebo
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Transient Hypothyroxinemia of Prematurity (THOP)
- Interventions
- thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Hour to 24 Hours
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Alcohol Dependence
- Interventions
- naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Obesity
- Interventions
- Home-based nutrition sessions and play group exercise, Group-based nutrition sessions and mail-out activities
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Violence, Sexual
- Interventions
- Empowerment Self Defense Training
- Behavioral
- Lead sponsor
- Hunter College of City University of New York
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Friedreich Ataxia
- Interventions
- MIB-626
- Drug
- Lead sponsor
- Metro International Biotech, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adverse Childhood Experiences, Endothelial Dysfunction
- Interventions
- Nicotinamide Riboside, Placebo
- Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Madison, Wisconsin
- Conditions
- Alzheimer's Disease (Incl Subtypes), Dementia
- Interventions
- MIB-626, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Lupus Erythematosus (Sle)
- Interventions
- Nicotinamide Riboside
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type2diabetes, Diabetic Kidney Disease
- Interventions
- Investigational Product - MIB 626, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cognitive Impairment, Sleep Quality
- Interventions
- Nicotinamide riboside, Placebo
- Dietary Supplement
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Buffalo, New York
- Conditions
- Cancer
- Interventions
- EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate), 99mTC-EC20 (Folic acid-technetium 99m conjugate)
- Drug
- Lead sponsor
- Endocyte
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Las Vegas, Nevada
- Conditions
- Vacterl Association, Congenital Malformation
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Skeletal Muscle
- Interventions
- Deuterated nicotinamide (D4-NAM) IV infusion, Skeletal muscle biopsy, Skin tissue biopsy
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 21 Years to 40 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Parkinson's Disease
- Interventions
- Gold Nanocrystals
- Drug
- Lead sponsor
- Clene Nanomedicine
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Parkinson's Disease
- Interventions
- Nicotinamide Riboside (NR), Oral placebo capsules
- Dietary Supplement
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
- Interventions
- App, Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
- Interventions
- QRX-3
- Drug
- Lead sponsor
- Ebima Clifford Okundaye
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Pasedena, Texas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Placebo Oral Tablet, GKT137831
- Other · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
- Conditions
- Cancer, Skin Fibroblasts, Muscle Weakness
- Interventions
- Nicotinamide Riboside (NR)
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Health Adult Subjects, Healthy Participants
- Interventions
- LathMized TM NAD+ (LNAD+), Control (placebo)
- Dietary Supplement · Other
- Lead sponsor
- BioNADrx Holdings, Inc. Bryleos
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington